Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Q In patients with atrial fibrillation (AF) at risk for ischaemic stroke, is ximelagatran non-inferior to warfarin in preventing stroke and systemic embolism?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Internal medicine ★★★★★★★ Cardiology ★★★★★★☆ Haematology ★★★★★★★
randomised controlled trial (Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation [SPORTIF]).
blinded (outcome assessors).*
mean 17.4 months.
259 hospitals, doctor’s offices, and clinics in 23 countries.
3410 patients ⩾18 years of age who had nonvalvular AF and ⩾1 additional risk factor for stroke: treatment for hypertension but blood pressure <180/100 mm Hg; age ⩾75 years; previous stroke, transient ischaemic attack (TIA), or systemic embolism; left ventricular dysfunction; or age …